- Home
- SNEX vs TOVX Comparison
SNEX vs TOVX Comparison
Compare SNEX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNEX
- TOVX
- Stock Information
- Founded
- SNEX 1924
- TOVX 2001
- Country
- SNEX United States
- TOVX United States
- Employees
- SNEX N/A
- TOVX N/A
- Industry
- SNEX Investment Bankers/Brokers/Service
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SNEX Finance
- TOVX Health Care
- Exchange
- SNEX Nasdaq
- TOVX Nasdaq
- Market Cap
- SNEX 3.3B
- TOVX 3.5M
- IPO Year
- SNEX 1994
- TOVX 2006
- Fundamental
- Price
- SNEX $94.66
- TOVX $1.14
- Analyst Decision
- SNEX
- TOVX Strong Buy
- Analyst Count
- SNEX 0
- TOVX 1
- Target Price
- SNEX N/A
- TOVX $6.00
- AVG Volume (30 Days)
- SNEX 173.7K
- TOVX 96.3K
- Earning Date
- SNEX 02-04-2025
- TOVX 11-12-2024
- Dividend Yield
- SNEX N/A
- TOVX N/A
- EPS Growth
- SNEX 6.85
- TOVX N/A
- EPS
- SNEX 7.96
- TOVX N/A
- Revenue
- SNEX $98,704,300,000.00
- TOVX N/A
- Revenue This Year
- SNEX N/A
- TOVX N/A
- Revenue Next Year
- SNEX N/A
- TOVX N/A
- P/E Ratio
- SNEX $11.94
- TOVX N/A
- Revenue Growth
- SNEX 64.52
- TOVX N/A
- 52 Week Low
- SNEX $61.68
- TOVX $1.14
- 52 Week High
- SNEX $106.77
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- SNEX 37.96
- TOVX 36.15
- Support Level
- SNEX $90.87
- TOVX $1.23
- Resistance Level
- SNEX $103.92
- TOVX $1.21
- Average True Range (ATR)
- SNEX 2.49
- TOVX 0.07
- MACD
- SNEX -1.61
- TOVX 0.01
- Stochastic Oscillator
- SNEX 21.42
- TOVX 0.00
About SNEX StoneX Group Inc.
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: commercial, Institutional, Retail, and Global Payments. Its customers include governmental and nongovernmental organizations, and commercial banks, brokers, institutional investors, and investment banks. The company operates in United States, South America, Europe, Middle East and Asia and other countries, out of which majority revenue is generates from Middle East and Asia Region.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.